Guida di laboratorio · Asse dell'ormone della crescita
Che cos’è l’IGF-1 LR3? Panoramica sulla ricerca relativa all’analogo dell’IGF-1 resistente all’IGFBP
What is IGF-1 LR3? It is an 83-residue recombinant analogue of insulin-like growth factor-1 with a 13-residue N-terminal extension and arginine in place of glutamate at position 3, which together sharply reduce binding to IGF-binding proteins. This guide explains the design, what “long” does and does not mean, and the published findings on potency and receptor binding.
Punti chiave
- IGF-1 LR3 has 83 residues (native IGF-1 has 70), formula C400H619N111O115S9 and mass about 9.1 kDa, with the three native disulfide bonds retained.
- Its design lowers affinity for IGF-binding proteins by roughly 1000-fold for IGFBP-3 and IGFBP-4 (Ballard et al., 1993), while receptor binding is reduced about 3-fold (Tomas et al., 1992).
- In rats it was cleared from plasma faster than IGF-1 because it does not associate with plasma binding proteins, so “long” refers to the extension, not to a longer half-life.
- Its main research uses are IGF-1 receptor signalling and cell culture, and it is not an approved medicine.
What is IGF-1 LR3?
So, what is IGF-1 LR3? IGF-1 LR3 (Long R3 IGF-I) is a recombinant analogue of human insulin-like growth factor-1. The variant was described by Francis et al. (1992), who made novel recombinant fusion-protein analogues of IGF-I to assess the relative importance of IGF-binding-protein and receptor binding for enhanced biological potency. In practice it is mostly used as a more potent IGF-1 receptor ligand in cell culture.
Solo per uso di ricerca. Questa panoramica riassume i risultati delle ricerche di laboratorio e sugli animali già pubblicati. Baltic Peptides fornisce questo composto a ricercatori qualificati per la ricerca in vitro e preclinica; non si tratta di un medicinale e non è destinato all’uso umano o veterinario.
Struttura chimica e specifiche
| Proprietà | Valore |
|---|---|
| Lunghezza | 83 residues (native IGF-1: 70) |
| Changes vs IGF-1 | N-terminal extension MFPAMPLSSLFVN plus Glu3→Arg |
| Disulfide bonds | Tre (modello IGF-1 nativo) |
| Formula molecolare | C400H619N111O115S9 |
| Peso molecolare | ≈9111.5 Da (average, with three disulfides) |
| Numero CAS | 946870-92-4 (supplier-listed) |
I confirmed that the 83-residue sequence, with three disulfide bonds, reproduces the formula and mass. The nine sulfur atoms come from six cysteines and three methionines. Because it is a folded protein, a mass check alone cannot show that the disulfides are paired correctly, which is why bioactivity assays are used alongside HPLC and mass spectrometry.
Storia delle scoperte e della ricerca
The analogues came from CSIRO laboratories in Adelaide, South Australia, where Francis, Ballard and colleagues studied how IGF-binding proteins limit IGF-I action. In the 1992 rat study from the same group, Tomas et al. found that two analogues that bind poorly to IGFBPs, des(1-3)IGF-I and LR3IGF-I, were about 2.5-fold more potent than IGF-I in dexamethasone-treated rats.
LR3 has since become a standard supplement in serum-free mammalian cell culture, because cells secrete IGFBPs that would otherwise sequester native IGF-1.
Mechanism: IGFBP escape and receptor activation
Binding proteins
IGFBPs sequester IGFs away from the type 1 IGF receptor and can inhibit IGF-stimulated mitogenesis, differentiation and survival, as Firth and Baxter (2002) review. IGF-1 has about 1000-fold higher affinity than LR3IGF-I for IGFBP-3, IGFBP-4 and total rat plasma binding proteins (Ballard et al., 1993).
Receptor binding and the “long” misnomer
Tomas et al. noted that LR3IGF-I binds about 3-fold less well than IGF-I to the type 1 IGF receptor, yet was striking in vivo. Ballard and colleagues found that LR3IGF-I was removed from plasma much more rapidly than IGF-I because it does not associate with plasma IGFBPs. “Long” refers to the extended sequence, so the analogue is more potent in IGFBP-rich settings but shorter-lived in rat plasma.
Principali aree di ricerca
- IGF-1 receptor signalling: PI3K/Akt/mTOR and Ras/MAPK activation in cell models.
- IGFBP biology: separating receptor-driven from binding-protein-mediated effects by comparison with native IGF-1.
- Cell culture and bioprocessing: serum-free media supplementation.
- Muscle cell biology: myoblast proliferation and differentiation in vitro.
Cosa dimostrano effettivamente gli studi pubblicati
| Tipo di prova | Cosa viene riportato |
|---|---|
| Dati chimici | Sequence length, extension, Arg3 change and formula are verifiable. |
| Studi sulla legatura | About 1000-fold lower IGFBP-3 and IGFBP-4 affinity and about 3-fold lower receptor affinity than IGF-I. |
| Studi sui ratti | About 2.5-fold greater potency than IGF-I in dexamethasone-treated rats (Tomas et al., 1992); faster plasma clearance than IGF-I. |
| Normativa | Not an approved medicine. The licensed IGF-1 product, mecasermin, is a native-sequence rhIGF-1, according to the supplier product page. |
Potency depends on the system. It is most striking where IGFBPs are abundant and smaller where they are absent.
Limiti scientifici e questioni aperte
- Potency gains are model-dependent and not a statement about outcomes outside experimental systems.
- Proper folding and disulfide pairing cannot be confirmed by mass alone.
- Receptor activation has mitogenic consequences, so experimental concentrations and cell types matter.
- It is not approved as a medicine, and IGF-1 and its analogues are on the WADA Prohibited List according to the supplier product page.
Considerazioni analitiche e di laboratorio
Intact-mass analysis should show about 9111.5 Da. SDS-PAGE and reverse-phase HPLC check purity, and a receptor-binding or cell-proliferation assay confirms bioactivity, since a protein can be pure but misfolded. Endotoxin matters for cell-culture work. As a folded protein, it is sensitive to freeze-thaw cycling, vigorous agitation and adsorption to plastic at low concentrations.
See how to store peptides and the guide to reading a peptide COA. Batch reports are on the COA page, and formats are on the IGF-1 LR3 product page.
Fonti e approfondimenti
- Francis G.L. et al. (1992). Novel recombinant fusion protein analogues of insulin-like growth factor (IGF)-I indicate the relative importance of IGF-binding protein and receptor binding for enhanced biological potency. J Mol Endocrinol 8(3):213-223. DOI
- Tomas F.M. et al. (1992). Insulin-like growth factor-I (IGF-I) and especially IGF-I variants are anabolic in dexamethasone-treated rats. Biochem J 282:91-97. PMC full text
- Ballard F.J. et al. (1993). Effects of interactions between IGFBPs and IGFs on the plasma clearance and in vivo biological activities of IGFs and IGF analogs. Growth Regul 3(1):40-44. PubMed
- Firth S.M. and Baxter R.C. (2002). Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 23(6):824-854. PubMed
Tutti i prodotti Baltic Peptides sono forniti esclusivamente per uso di ricerca in laboratorio. Non si tratta di medicinali, integratori o alimenti e non sono destinati all’uso umano o animale. Il presente articolo riassume le ricerche pubblicate a solo scopo didattico e non descrive alcun utilizzo sulle persone.
Domande frequenti
Domande frequenti
What is IGF-1 LR3?
What does LR3 stand for?
What is the molecular weight and formula of IGF-1 LR3?
In che modo l’IGF-1 LR3 differisce dall’IGF-1 nativo?
Does Long R3 mean a longer half-life?
Why is IGF-1 LR3 used in cell culture?
Is IGF-1 LR3 an approved medicine?
Continua a leggere
Altre letture consigliate
IGF-1 LR3
Current batches, formats and the COA for IGF-1 LR3.
What is AOD-9604?
A growth-hormone fragment studied separately from the IGF-1 axis.
Come leggere un peptide COA
The checklist for any certificate of analysis.
Research-grade IGF-1 LR3, tested before it ships
Risultati indipendenti delle analisi al HPLC o e alla spettrometria di massa per ogni lotto spedito dall’UE.
